ERVEBO vaccination for frontline workers during the 2026 Bundibugyo outbreak in the DRC

Eligibility criteria for enrolment in the BRAVO cohort

Inclusion criteria:

The following FLWs will be eligible for enrolment in the study:

* Aged 18 years or older
* Currently working, or holding a signed work assignment to work, in the following settings within BVD-affected study areas:

  * Ebola health facilities, including physicians, nurses, nurse assistants, laboratory technicians, pharmacists, IPC personnel, environmental hygiene and waste management personnel, mental health and psychosocial support staff, cleaners, security personnel, administrative and any other potentially exposed staff
  * Health facilities providing non Ebola clinical care, including but not restricted to services such as emergency care, general outpatient or inpatient care, surgery, laboratory services, maternity, haematology, infectious diseases, paediatrics
  * Community based or outbreak response activities, including surveillance and contact tracing teams, drivers and ambulance teams, vaccination teams, community health workers and personnel responsible for post mortem swabbing or burial related activities
  * Any other personnel whose duties involve direct contact with suspected or confirmed Ebola cases, their bodily fluids, contaminated materials, or environments where Ebola transmission may occur.
* Able and willing to complete the informed consent process and comply with study procedures

Exclusion criteria :

There are no exclusion criteria to participate in the BRAVO cohort. If a FLW chooses to not receive the ERVEBO vaccine, they can be enrolled as part of the control group.

To be part of the vaccinated group, additional criteria apply as below:

Eligibility criteria specific to vaccination

Inclusion criteria:

* Enrolled in the BRAVO study (eligible and gave informed consent)
* Voluntary chooses to receive vaccination

Exclusion criteria:

* Voluntarily chooses not to receive vaccination
* Self reported clinically significant immunodeficiency (e.g. a known immunodeficiency condition that, in the judgment of the study clinician, may affect the safety and effectiveness of ERVEBO® vaccination, such as HIV infection with an AIDS-defining illness, CD4+ T-lymphocyte count \<200 cells/mm³, HIV/AIDS or another severe immunocompromising condition). Stable HIV infection on antiretroviral therapy with preserved immune function is not a contra-indication)
* History of severe allergic reaction or anaphylaxis associated with a vaccine or vaccine component
* Any other condition or reason not otherwise specified in the protocol which, in the opinion of the investigator or delegated clinician, would contraindicate administration of ERVEBO® or make vaccination inappropriate. Any decision to withhold vaccination on this basis will be documented, including the rationale for exclusion.